Tilelizumab
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Tilelizumab, covering 2021-04-29 to 2022-06-14. Get the full timeline:
Most recent: Clinical Trial Update: Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study [Phase 2]